Jefferies initiates Gyre Therapeutics stock with Buy rating, $16 target
PositiveFinancial Markets

Jefferies has initiated coverage of Gyre Therapeutics with a Buy rating and set a target price of $16 per share. This positive outlook reflects confidence in Gyre's potential for growth and innovation in the biotech sector, which could attract investors looking for promising opportunities. The endorsement from a reputable firm like Jefferies could also enhance Gyre's visibility in the market.
— Curated by the World Pulse Now AI Editorial System